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Abstract
The objective of this study is to evaluate the efficacy and potential mechanism of action of type-II collagen
bifunctional peptide inhibitor (CII-BPI) molecules in suppressing rheumatoid arthritis in the collagen-induced arthritis
(CIA) mouse model. CII-BPI molecules (CII-BPI-1, CII-BPI-2, and CII-BPI-3) were formed through conjugation
between an antigenic peptide derived from type-II collagen and a cell adhesion peptide LABL (CD11a237-246) from
the I-domain of LFA-1 via a linker molecule. The hypothesis is that the CII-BPI molecules simultaneously bind to
MHC-II and ICAM-1 on the surface of APC and block maturation of the immunological synapse. As a result, the
differentiation of naïve T cells is altered from inflammatory to regulatory and/or suppressor T cells. The efficacies of
CII-BPI molecules were evaluated upon intravenous injections in CIA mice. Results showed that CII-BPI-1 and CII-
BPI-2 suppressed the joint inflammations in CIA mice in a dose-dependent manner and were more potent than the
respective antigenic peptides alone. CII-BPI-3 was not as efficacious as CII-BPI-1 and CII-BPI-2. Significantly less
joint damage was observed in CII-BPI-2 and CII-2 treated mice than in the control. The production of IL-6 was
significantly lower at the peak of disease in mice treated with CII-BPI-2 compared to those treated with CII-2 and
control. In conclusion, this is the first proof-of-concept study showing that BPI molecules can be used to suppress
RA and may be a potential therapeutic strategy for the treatment of rheumatoid arthritis.
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Abbreviations
LFA-1: Leukocyte Function-Associated Antigen-1; MHC-II: Major
Histocompatibility Complex-II; ICAM-1: Intercellular Adhesion
Molecule-1; APC: Antigen-Presenting Cells; TNF: Tumor Necrosis
Factor; IFN: Interferon; IL: Interleukin; Th: T-helper
Introduction
Rheumatoid Arthritis (RA) is an autoimmune disease that causes
pain, stiffness, chronic inflammation, and deformity due to cartilage,
bone, and ligament destruction in the joints [1]. Although the etiology
of RA is not fully understood, it has been suggested that the cause of
the disease is the attack on the host joints by immune cells along with
the generation of lymphocytes that release inflammatory cytokines
such as TNF-α, IFN-γ, and IL-1, IL-6 [2-5]. Th1 cells infiltrate the
synovium where they release pro-inflammatory cytokines and
chemokines that promote macrophage and neutrophil infiltration and
activation [1,4,6]. Th17 cells, a subset of Th cells, have also been
implicated in autoimmune diseases, including rheumatoid arthritis
[3,7]. Another possible cause is that the body fails to activate
regulatory T cells (T-reg); thus, enhancing the production of T-reg
may be one therapeutic strategy to suppress RA and other
autoimmune diseases [8-12].
Many treatments are available for preventing joint degradation and
inflammation; however, there is not yet a cure for RA. Some of the
drugs used in the treatment of RA include Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs), corticosteroids, and traditional
Disease-Modifying Anti-Rheumatic Drugs (DMARDS) [13-15].
Methotrexate is one of the most commonly used traditional DMARD.
Although it is effective, its use is sometimes discontinued due to
toxicity. It is reported that approximately 30% of RA patients abandon
treatment because of toxicity issues [16]. There are also newer
biological DMARDS (e.g., etanercept, infliximab, adalimumab,
rituximab, and abatacept) that have been used in the treatment of RA.
Biologic modifiers provide therapeutic response via lowering TNF-α
levels in the systemic circulation [17,18], blocking T-cell activation
[13,14,19,20], and depleting B cells [21,22]. With the advent of these
targeted therapies used alone or in combination with other drugs
[13,14], standard care for patients with RA has markedly improved.
However, many patients still experience less than adequate control
because they either do not respond to treatment or become resistant to
it. Also, some patients respond to the treatments, but develop
complications due to undesirable drug safety profiles. Safety of RA
therapies is always a concern because most of these treatments are
generally immunosuppressive causing a risk of opportunistic infection
or increased serious adverse side effects.
Further improvement in RA treatment and management can be
achieved through introduction of innovative therapies that provide
better efficacy and safety profiles. Our group discovered a new strategy
to suppress or prevent the development of autoimmune diseases by
controlling the activation of immune cells in an antigen-specific
manner using Bifunctional Peptide Inhibitor (BPI) molecules [23-28].
In this strategy, a cell adhesion molecule is conjugated to an antigenic
peptide via a spacer to make BPI molecules. Studies on PLP-BPI and
GAD-BPI have been shown to induce immunotolerance in
experimental allergic encephalomyelitis (EAE) and type-1 diabetes
(T1D), respectively [23-28].
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In this study, we investigated the potential of using BPI molecules
to induce tolerance in rheumatoid arthritis. We developed a novel type
of bifunctional peptide inhibitor (BPI) molecule called CII-BPI (i.e.,
CII-BPI-1, CII-BPI-2, and CII-BPI-3; Table 1) and evaluated their
efficacy in suppressing collagen-induced arthritis (CIA) in a mouse
model. These molecules are composed of antigenic peptides from
collagen II (i.e., CII256-270, CII707-721, and CII11237-1249) linked via a
spacer to a cell adhesion peptide called LABL. The LABL peptide is
derived from the I-domain of αL-integrin (CD11a237-246), which binds
to ICAM-1. At the molecular level, these molecules may block the
formation of the immunological synapse necessary for T-cell
activation [28]. The efficacies of CII-BPI molecules to suppress the
progress of RA were compared to those of the respective parent
antigenic peptides from CII in the CIA mouse model. The effect of














Ac: Acetyl group; Acp: ε-aminocaproic acid; G: Glycine
Table 1: Peptide Sequences
Materials and Methods
Animals
The DBA/1J male mice utilized in study-I and -II were purchased
from Jackson Laboratory (Bar Harbor, ME). For study-III, DBA1BO-
M male mice were purchased from Taconic Farms (Germantown,
NY). All mice were housed under specific pathogen-free conditions at
the animal facility at The University of Kansas approved by the
Association for Assessment and Accreditation of Laboratory Animal
Care. All experimental procedures using live mice were approved by
the Institutional Animal Care and Use Committee at The University of
Kansas.
Peptide Synthesis
Peptides used in this study (Table 1) were synthesized using a solid
phase peptide synthesizer (Pioneer; Perceptive Biosystems,
Framingham, MA) on a polyethylene glycol-polystyrene resin
(Applied Biosystems, Foster City, CA) with 9-
fluorenylmethyloxycarbonyl-protected amino acid chemistry.
Cleavage of the peptides from the resin and removal of the protecting
groups were carried out using trifluoroacetic acid in the presence of
scavengers. Reversed-phase High-Performance Liquid
Chromatography (HPLC) using a C18 column was employed to purify
the crude peptide using a gradient of solvent A (95% H2O with 0.1%
trifluoroacetic acid and 5% acetonitrile) and solvent B (100%
acetonitrile). The pure peptide was analyzed by analytical HPLC using
an analytical C18 column and the identity of the peptide was
confirmed by matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry.
Induction of CIA and Therapeutic Study
For study-I and -II, bovine type II collagen (CII, Elastin Products,
Owensville, MO) was dissolved in 0.05 M acetic acid overnight at 4°C
at a concentration of 6 mg/ml. CFA was prepared by addition of killed
mycobacterium tuberculosis H37RA (Difco, Detroit, MI) to IFA
(Difco) at a concentration of 8 mg/ml. The solution of CII (6 mg/ml)
was emulsified in an equal volume of CFA. Six-to-eight-week-old
DBA/1J mice were immunized with 100 µl of emulsion containing 300
µg CII and 400 µg mycobacteria injected intradermally at the tail base.
After 21 days, all mice received a booster dose of 100 µl of emulsion
containing 300 µg CII injected intradermally at the tail base.
For study-I, the mice received intravenous (i.v.) injections of CII-
BPI-1 and CII-1 peptides (100 nmol/injection) on days 19, 22, and 25.
In another group, mice were injected with 5 mg/kg in 100 μl of MTX-
cIBR for 10 days from day 19. For study-II, the same disease induction
protocol was followed, with the mice receiving i.v. injections of CII-
BPI-2, CII-BPI-3, CII-2, and CII-3 (100 nmol/injection) on days 19,
22, and 25. For study-III, a readily available chicken collagen/CFA
emulsion, containing 1.0 mg/ml of type II chicken collagen and 2.0
mg/ml of Mycobacterium tuberculosis (Hooke Laboratories,
Lawrence, MA), was injected intradermally. This was followed by an
intradermal IFA emulsion injection, containing 1 mg/ml of chicken
type-II collagen, on day 21. The mice were given i.v. injections of
peptides (100 nmol/injection) on days 17, 22, 25, and 28. Disease
progression was evaluated by measuring the increase in paw swelling
of the fore limbs as well as hind limbs. Paw volume was determined by
measuring the volume of water displaced by the paw before and after
disease induction. Paw volume determined prior to disease induction
was used as the baseline. Percent increase in paw volume, ∆Vpaw, was
calculated using the equation below:
∆Vpaw = (VSwollen – VBaseline)/VBaseline*100%
Histopathology of the Joints
Development of CIA in DBA/1J mice was also assessed
histologically. In study-II, both hind limbs were removed 30 days after
the second immunization and fixed in formalin prior to analysis.
Arthritic changes and joint damage were individually scored for
articular cartilage damage, pannus formation, synovial membrane
thickening, synovial capsule thickening, and inflammatory cell
infiltrate. The score was totaled as: 0, no lesions; 1, mild changes; 2,
moderate changes; 3 and 4, severe changes. The histopathology
evaluation was done by Dr. Stan Kosanke at the University of
Oklahoma Health Sciences Center.
Determination of Cytokine Levels in Serum in DBA1BO-M
mice In Vivo
To understand the mechanism of action of CII-BPI in inhibiting the
progression of CIA, cytokine levels in serum obtained from treated
and untreated mice were measured. First, we wanted to look at the
effect of peptide treatment in the production of IL-6, a pro-
inflammatory cytokine on day 31 immediately following treatment
and on day 44 at the end of the study. Second, we looked at the effect
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of dose on IL-6 serum levels following three and four injections of
peptide. Third, we also looked at other different cytokines present in
serum of treated and untreated mice. Cytokine production was
measured by obtaining blood samples on indicated days from the
study-III group without sacrificing the mice. Blood samples were
allowed to clot overnight at 4°C before centrifuging at 5,000 rpm for
10 minutes the next day. Serum was collected and stored at -80°C until
analysis. Serum cytokine analysis was performed using a fully
quantitative ELISA-based Q-PlexTM Mouse Cytokine-Screen (Quansys
Biosciences, Logan, UT).
Statistical Analysis
Statistical differences among the groups in volume displacement,
histopathological score, and serum cytokine levels were determined by
one-way analysis of variance followed by Fisher’s least significant
difference. All analyses were performed using StatView (SAS Institute,
Cary, NC).
Results
Suppression of CIA by CII-BPI
In study-I, the animals (DBA/1J male mice) injected with bovine
collagen in CFA developed signs of rheumatoid arthritis
approximately four days after administration of the booster dose on
day 21; these signs included inflammation of their limbs as well as
joint damage (Figure 1A). Changes in paw volume due to swelling
were significantly lower in CII-BPI-1-treated mice than in those
treated with PBS (Figure 1A; p<0.01 from days 40 to 44). Also, CII-1
peptide-treated mice had significant suppression of arthritis compared
to the PBS-treated control group (p<0.01 from days 40 to 44). CII-
BPI-1 peptide had better CIA suppressive activity than CII-1 peptide
(Figure 1A; p<0.01, through days 40-44), suggesting that forming BPI-
type molecules improves the biological activity of the peptide. The
positive control treatment, MTX-cIBR (5 mg/kg), suppressed arthritis
better than PBS (p<0.01, through days 40-44) and with almost the
same potency as the CII-BPI-1 peptide (p>0.10). MTX-cIBR has been
shown to be effective in suppressing arthritis in adjuvant arthritis rats
[29].
In study-II, the efficacies of CII-BPI-2 and CII-BPI-3 were
compared to those of their respective antigenic peptides, CII-2 and
CII-3, in suppressing CIA using DBA/1J male mice (Figure 1B). Study
II was carried out using the same protocol as illustrated in study I.
Bovine type II collagen was used to induce CIA in male DBA1/J mice.
After disease induction these animals were treated with three
injections of the peptides. Suppression of inflammation was monitored
by measuring changes in paw volume and histopathology analysis of
the limbs on day 30. Our results showed that both CII-BPI-2 and CII-2
had significantly (p<0.001) lower paw swelling compared to PBS
(Figure 1B); suggesting that these two peptides had some activity in
suppressing inflammation of the limbs. We did not see any statistical
significance (p>0.05) between CII-BPI-2 and CII-2 peptides. However
our data showed that CII-BPI-2 had a moderately stronger
suppression of inflammation than CII-2 as illustrated by changes in
paw volume (Figure 1B). It is clear that CII-BPI-2 has better efficacy
than CII-BPI-3 and CII-3 peptide (p<0.05, through days 40-44). In
contrast to other peptides, there is a trend that CII-3-treated mice had
a higher paw volume compared to those treated with PBS; suggesting
that CII-3 exacerbated the disease.
Figure 1: In vivo efficacy of CII-BPIs and their respective antigenic peptides in suppressing collagen-induced arthritis in CIA mouse model.
PBS and MTX-cIBR were used as negative and positive controls. DBA/1J mice were immunized intradermally at the tail base with CII/CFA
on day 0 and followed by a booster dose at day 21 as described in Material and Methods section. Intravenous injections of peptides (100 nmol/
injection) were administered on days 19, 22, and 25. For the MTX-cIBR group, mice were injected with 5 mg/kg in 100 uL of MTX-cIBR for
10 days beginning at day 19. The changes in paw volume were measured daily. The results are expressed as the mean ± standard error (n=7–
9). A, Study I shows evaluation of CII-BPI-1, CII-1, and MTX-cIBR. B, Study II shows efficacies of CII-BPI-2, CII-BPI-3, CII-2, and CII-3.
Statistical values conducted on days 40-44 for changes in paw volume compared with PBS were as follows: CII-BPI-1, p<0.01; CII-1, p<0.01;
CII-BPI-2, p<0.0001; CII-BPI-3, p<0.05; and CII-2, p<0.001.
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In contrast to our studies with other models of autoimmune disease
for example EAE mouse models, we observed that although we were
able to induce CIA in male DBA1/J mice using bovine type II collagen
we had a high variability in disease induction as well as severity of the
disease. This could be one of the contributing factors that made it
difficult for us to clearly make a distinction between the activities of
these peptides. To improve on the reproducibility of our
investigations, we switched to using chicken type II collagen for
disease induction. Others have shown that disease induction using
chicken type II collagen had a higher incidence and disease severity
compared to other native type II collagen [30]. We also used male
DBA1BO-M mice instead of male DBA1/J mice that were used in
study I and II. Thus in study-III, DBA1BO-M male mice were used,
and the disease was stimulated using chicken collagen in CFA.
DBA1BO-M mice developed more severe clinical arthritis than did the
DBA/1J mice utilized in study-I and -II. According to the percent
changes in paw swelling of all four limbs (Figure 2A), it is clear that 4
injections of CII-2 were significantly more effective than 3 injections
of CII-2 (p<0.001, through days 34-44). Although 4 injections of CII-
BPI-2 were better than 3 injections, it was difficult to differentiate the
efficacies of 3 and 4 injections of CII-BPI-2 peptide. In some instances
such as evaluation of the hind limbs (Figure 2B), there was a similar
trend showing that 4 injections of CII-BPI-2 were more effective than
either 3 injections of CII-BPI-2 but the data did not show any
significant difference. However, 3 injections of CII-BPI-2 was
significantly better than 3 injections of CII-2 peptide (p<0.001,
through days 34-44), suggesting that CII-BPI-2 is more potent than
CII-2 peptide. In this animal model, three injections of CII-2 peptide
did not show any efficacy in suppressing the changes in paw volume.
These results indicate that CII-BPI-2 is more potent than CII-2
peptide and that the activity of these peptides is dose-dependent.
Figure 2: In vivo activity of the CII-2 and CII-BPI-2 peptides in suppressing collagen-induced arthritis in the mouse model after varying
injections. In study-III, DBA1BO male mice were immunized with CII/CFA intradermally and given a booster dose on day 21 as described in
Materials and Methods. The mice were then given three i.v. injections of peptides (100 nmol/injection) on days 17, 22, and 25 or four
injections on days 17, 22, 25, and 28. The disease progression was observed by monitoring the changes in the volume of (A) all four paws or
(B) just the hind paws. Results are expressed as the mean ± standard error (n=7–9). Statistical values showed that three or four injections of
CII-BPI-2 and CII-2 were significantly better than PBS (p<0.0001, days 34-44). Four injections of CII-2 were more effective compared to three
injections (p<0.001, days 34-44). Three injections of CII-BPI-2 were better than three injections of CII-2 (p<0.001, days 34-44). Data from all
four limbs as well as hind limbs alone showed that there was a trend indicating that four injections of CII-BPI-2 were better than three
injections.
Histopathological Analysis
To evaluate the effect of CII-BPI molecules in suppressing CIA, the
histopathology of the joints of the animals was examined for cartilage
erosion and cell infiltration in the joint space. For the untreated
arthritic mice, the knee joints had moderate evidence of articular
cartilage damage with pannus formation (Figure 3A). The synovial
membrane and capsule were both markedly thickened as a result of
pannus formation and inflammatory cell infiltration. The synovial
linings were hyperplastic with sloughing of synoviocytes into the joint
space. The inflammatory cellular infiltrate consisted of a mixture of
mostly synovial macrophages, neutrophils, and lymphoplasmacytic
cells. In the untreated group, the chronic inflammation destroyed the
joint lining, including the cartilage and other nearby supporting
structures, such as bone (Figure 3B). The formation of pannus is a
result of overgrowth of the synoviocytes and the observed
accumulation of inflammatory cells that led to deformed cartilage and
bone, which agrees with the observed clinical scores.
For mice treated with CII-2 peptide, four out of six knee joints
appeared normal (Figure 3C), and the two remaining joints had very
mild evidence of synovial membrane thickening with pannus
formation, which falls within normal limits. Minimal evidence of
chronic inflammation and articular cartilage damage were observed in
the mice group treated with CII-BPI-2 (Figure 3D). Two of the six
knee joints from the mice treated with CII-BPI-2 had very mild
evidence of synovial membrane thickening. Mice treated with CII-2
and CII-BPI had a lower incidence of inflammation and cell
infiltration into the joint space as well as cartilage damage. Overall,
mice treated with CII-2 and CII-BPI-2 peptides had significantly lower
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joint histopathological scores than the PBS-treated group (p<0.0001)
(Figure 4).
Figure 3: Histological analysis of knee joints in peptide- and PBS-
treated mice. A & B, Images of the joints of PBS-treated mice with
articular cartilage damage as well as a collection of cellular exudates
within the joint spaces. C, Image of mouse joint treated with CII
peptide, which appears essentially normal. D, Image of the joint of a
mouse treated with CII-BPI-2 showing minimal inflammation. J:
Joint space; M: Synovial membrane; P: Pannus formation; A:
Articular cartilage.
Figure 4: Comparison of the mean scores of joint histopathology of
normal untreated mice and diseased mice treated with PBS, CII-
BPI-2, and CII-2 peptides in the mouse CIA model. CII-BPI-2 and
CII-2 had significantly (p<0.0001) lower scores compared with PBS.
The CII-treated and CII-BPI-2-treated mice had significantly lower
cartilage erosion and inflammatory infiltrates in the joint space
compared to those treated with PBS. Although we did not see any
significant difference in the histopathological analysis of the joint
limbs in mice treated with CII-BPI-2 and CII-2, the results showed
that CII-BPI-2 had a slightly stronger effect in amelioration erosion
and infiltration of the joints. As mentioned above, one of the reasons
why we could make a distinction between CII-2 and CII-BPI-2 was
because of the high variability in disease incidence and severity. We
observed that using bovine type II collagen to induce CIA in male
DBA1/J mice gave a high variability in disease incidence and severity.
Also, the dose is important. At a lower dose, we could distinguish the
activities of the two peptides in suppressing CIA in male DBA1BO-M
mice but we did not see any significant difference when we increased
the dose or frequency of administration.
Cytokine Serum Levels in DBA1BO-M Mice In Vivo
To determine the effect of the CII-BPI treatment in study-III on
cytokine levels, the levels of different cytokines in the serum were
determined using ELISA on day 31 at around the disease peak and on
day 44 when the arthritis swelling was at the plateau region. On day
31, the IL-6 levels were significantly lower in mice injected 3 times
with CII-BPI-2 than in those treated with PBS (p<0.0001) and CII-2
(p<0.0001) (Figure 5A). However, the CII-2-treated group had higher
serum IL-6 levels than the PBS group (p<0.0001). Once the arthritic
swelling reached a plateau on day 44 (Figure 5A), the serum IL-6
concentration of the CII-2 group significantly decreased compared to
that of the PBS-treated group (p<0.0001). During periods of disease
remission, there was no significant difference was observed in IL-6
levels between CII-2- and CII-BPI-2-treated mice. These results
suggest that although CII-BPI-2 and CII-2 were efficacious in
suppressing CIA, IL-6 serum levels indicate that may have different
mechanisms of suppressing arthritis.
In the groups injected four times with treatment peptides, the
serum level of IL-6 in the CII-2 group was nearly three times higher
than that seen in the PBS-treated group at the peak of the disease on
day 31 (p<0.0001)(Figure 5B). No significant difference between IL-6
concentrations of CII-BPI-2 and PBS was observed on day 31. Analysis
of the mouse cytokine levels at the end of the study (day 44) showed
that IL-6 levels were lower in both the CII-2 and CII-BPI-2 groups
when compared to the PBS group (p<0.0001). As with day 31, the
results of the IL-6 levels obtained from mouse serum on day 44 suggest
that tethering an adhesion molecule to the antigenic peptide in CII-
BPI-2 may produce a different mechanism of action than that of CII-2
peptide. It is difficult to suggest that similar IL-6 levels in CII-BPI-2
and CII-2 on day 44 imply that the two peptides had similar activity.
There is a possibility that on day 44, the disease was entering a
remission phase as shown by paw swelling essentially reaching a
plateau and there is less inflammation at that point. Thus, like most
autoimmune diseases, there is more intense inflammation prevalent
during the initial phase but reduced inflammatory activity during the
secondary and progressive phase [31]. It is plausible that during
remission the effect of the two peptides on IL-6 production is
essentially over and what we were observing is just the clearance phase
of IL-6 from systemic circulation on day 44. Thus, we would anticipate
significantly lower IL-6 levels in the two treatment groups.
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Figure 5: The serum cytokine levels of IL-6 of mice treated with
PBS, CII-2, and CII-BPI-2 on days 31 and 44. A, Mice treated with
three injections of CII-BPI-2 have significantly lower levels of IL-6
in the serum than those injected with PBS (*, p<0.0001) and three
injections of CII-2 (#, p<0.0001). Serum IL-6 levels are significantly
higher on day 31 in the mice treated with CII-2 than in PBS-treated
mice (‡, p<0.0001). Serum levels of the cytokine IL-6 are
significantly lower on day 44 after three injections of CII-2 (*,
p<0.0001) and CII-BPI-2 (*, p<0.0001) compared to PBS. A
significant difference between IL-6 levels of CII-2 and CII-BPI-2 on
day 44 was not observed. B, Comparison of serum IL-6 levels of
mice treated with four injections of PBS, CII-2, and CII-BPI-2 on
days 31 and 44. Serum IL-6 levels are significantly higher in the
CII-2 group compared to the PBS group (‡, p<0.0001) and CII-
BPI-2 (*, p<0.0001). Significant differences between IL-6 levels of
CII-BPI-2 and PBS were not observed. On day 44, serum IL-6 levels
were significantly higher in the PBS-treated group compared to the
CII-2 (*, p<0.0001) and CII-BPI-2 groups (*, p<0.0001). No
significant difference in IL-6 levels was observed between CII-2 and
CII-BPI-2 treated groups on day 44.
Additional cytokines evaluated in serum of CII-BPI-2 and control
provided a better insight into the mechanism of action. Our studies
showed that CII-BPI-2 had significantly lower (p<0.01) pro-
inflammatory cytokines (e.g., IFN-γ, IL-17, and TNF-α) compared to
the control (Figure 6). On the other hand, we observed significantly
higher (p<0.001) levels of IL-10 in CII-BPI-2 treated mice compared to
the control group. All these findings suggest that CII-BPI-2 had a
suppressive effect on pro-inflammatory cytokines while promoting the
production of cytokines associated with regulatory T cell phenotypes.
Figure 6: The serum pro-inflammatory and anti-inflammatory
cytokine levels of mice treated with PBS and CII-BPI-2 on day 31.
Mice treated with three injections of CII-BPI-2 have significantly
lower levels of pro-inflammatory cytokines (e.g., IFN-γ, IL-17, and
TNF-α) in serum than those injected with PBS (*, p<0.01 and ‡,
p<0.001). Furthermore, serum IL-10 levels were significantly higher
(p<0.001) in CII-BPI-2 groups compared to the control group.
Discussion
Auto-reactive T cells have been implicated in the onset and
progression of autoimmune diseases, including multiple sclerosis
(MS), type-1 diabetes (T1D), and rheumatoid arthritis (RA). These
auto-reactive T cells have been shown to be activated via the formation
of an “immunological synapse” at the interface between the T cells and
APC [32-34]. Differentiation of naïve T cells to auto-reactive T cells is
strongly dependent on the type of the co-stimulatory signal involved
in the formation of the immunological synapse. A vast number of
studies have demonstrated that administration of soluble antigenic
peptides can induce immune tolerance [35-37]. It is thought that
soluble antigenic peptides bind to empty MHC-II on the surface of
immature dendritic cells and, in the absence of a co-stimulatory signal,
cause the naïve T cells to differentiate into T-regs [35].
The extracellular matrix of cartilage consists mainly of type II (CII)
collagen. CII, like myelin basic protein, can elicit tissue-specific
autoimmune disease [38-40]. Some collagen derived peptides (e.g.,
CII256-270, CII707-721, and CII1237-1249) have been used induce
immunotolerance and have been shown to hinder the progression of
CIA [41,42]. The selection of CII peptides used in this the present
study was based on previous studies showing that certain epitopes
such as CII256-270 can bind to I-Aq MHC class II molecules [40,43].
Experiments with CII256-270 have also shown that this peptide
sequence can inhibit the progression of CIA [40,44]. It has been
suggested that CII260-267 is the immunodominant core [40,44].
Another major immunodominant epitope (CII707-721, CII-1) that we
studied has previously been found to elicit a significant proliferative T-
cell response [41]. This peptide contains a combination of two
overlapping core sequences of CII704-712 and CII710-718 [41]. CII707-721
acetylated at the N-terminus and amidated at the C-terminus has also
been shown to strongly induce proliferation and that IFN-γ release
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correlates well with the proliferative responses induced by CII707-721
[41]. CII1237-1249 or CII-3 peptide was selected based on its ability to
selectively bind to the RA-associated DR4 MHC molecule [45-47].
Because CII1237-1249 and CII707-721 have not been studied as extensively
as CII256-270, their potential mechanisms have not been well
elucidated. The susceptibility of mice to CIA is confined mostly to
MHC type I-Aq [43].
The potential of antigenic peptides use in the treatment of
autoimmune diseases can be improved via use of bifunctional peptide
inhibitors (BPI). Here, we can expect that the CII-BPI peptide will
selectively block the activation of a subpopulation of T cells that
recognizes the collagen peptide-MHC-II complex without eliminating
the ability of the host to activate subpopulations of T cells that could
fight pathogenic infections. The hypothesis is that BPI molecules
target and bind to the molecular components of the immunological
synapse; thus, inhibiting formation of the immunological synapse at
the interface of T cell and antigen-presenting cell [28,48]. Co-capping
experiments with GAD-BPI showed that I-Ag7 and ICAM-1 receptors
were highly co-localized on the surface of GAD-BPI-treated APC
compared to APC treated with a mixture of unlinked peptides
(GAD208-217 and LABL) [28]. Also, binding of GAD-BPI to APC was
blocked by either anti-I-Ag7 or anti-ICAM-1 mAbs [28]; indicating
that BPI molecules can tether the two signals thus preventing their
translocation and eventual maturation of the immunological synapse.
In vivo efficacy results showed that PLP-BPI and GAD-BPI molecules
were effective in the suppression of EAE [26,27,49] and T1D,
respectively, in non-obese diabetic (NOD) mice [28]. Furthermore,
studies with PLP-BPI showed that PLP-BPI was more effective in
disease suppression compared to the antigenic peptide alone (i.e.,
PLP139-151), CD11a237-246 peptide alone (i.e., LABL), unlinked mixture
of PLP139-151 and LABL, or other control peptides [49]. Because BPI
molecules were more effective than the parent antigenic peptides alone
in suppressing autoimmune disease in animal models, this suggests
that the cell adhesion peptide (i.e., LABL portion) in BPI as well as BPI
structure has an important role in the in vivo activities of BPI
molecules. Results from this study showed that BPI molecules (e.g.,
CII-BPI-1 and CII-BPI-2) formed by conjugating antigenic peptides
derived from collagen to adhesion peptides have greater efficacies in
suppressing arthritis in CIA mice than their respective parent
antigenic peptides (CII-1 and CII-2). It was also found that neither
CII-BPI-3 nor CII-3 peptides were effective in preventing the progress
of arthritis, suggesting that the sequence of the antigen was not
appropriate for inducing tolerance in this model.
Our previous work with PLP-BPI in EAE mouse model showed that
PLP-BPI-treatment increased TGF-β and IL-10 production, suggesting
the involvement of T-reg [28]. Also, both PLP-BPI and GAD-BPI
enhanced the production of IL-4, indicating the involvement of Th2
differentiation and proliferation. Furthermore, the PLP-BPI-treated
animals had lower IL-17 than those treated with PBS, indicating the
suppression of Th17 proliferation [27]. Researchers have recently
confirmed the importance of the IL-17-producing Th17 cells in CIA.
In two separate experiments, the absence of Th17 lymphocytes in mice
deficient in IL-17 and the administration of anti-IL-17 antibodies have
been shown to significantly reduce the severity of CIA [50,51]. Others
have also shown that IL-17-deficient mice could markedly suppress
CIA by curbing the activation of autoantigen-specific T cells and B
cells in the sensitization phase of CIA. Similarly, altered peptide ligand
(APL) molecules from collagen II have been shown to suppress
arthritis by the expansion of T-reg and lowering of Th1 and Th17
[52,53]. IL-17 has been reported to activate osteoclasts and induce the
production of various cytokines by macrophages, monocytes, and
synoviocytes (IL-6, IL-8, IL-1, and TNF-α) [11,54,55].
Cytokines such as IL-6 and IL-21 have been implicated in the
induction of Th17 [55-57]. IL-6 has been shown to induce Th17
differentiation in both humans and mice. A study by Kelchtermans et
al. showed that a transfer of T-regs not only significantly improves
CIA but also lowers TNF-α and IL-6 levels in mouse sera [11]. The
decreased levels of mouse IL-6 cytokine in mouse sera that we
observed would suggest that CII-2 and CII-BPI-2 might possibly
suppress CIA by regulating the immune cells responsible for arthritis
[8]. In the EAE mouse model, it was also shown that a deficiency of
IL-6 shifted the immune response away from an immunogenic role to
a protective one [58]. Our results suggest that CII-BPI-2 could possibly
be altering the differentiation of naïve T cells into T-regs while
suppressing pro-inflammatory T cells.
It is interesting to note that even though CII-2 (i.e., CII256-270)
antigenic peptide eventually lowers IL-6 levels, these levels were still
found to be significantly higher during the peak of the disease in
CII-2-treated mice than in the control group. Mice injected three
times with CII-BPI-2 (i.e., CII256-270-BPI) showed significantly lower
levels of the inflammatory IL-6 cytokines on day 31 than did either
CII-2- or PBS-treated mice. In contrast, four injections of CII-BPI-2
did not produce any significant difference between the CII-BPI-2- and
PBS-treated mice. Given that four injections of either CII-BPI-2 or
CII-2 were effective in the suppression of CIA as demonstrated by the
clinical paw data, it is plausible that injection of soluble antigenic
peptide resulted in a transient increase in IL-6 levels. CII-BPI-2 has an
antigenic peptide component in it, and more injections led to a slight
increase in IL-6 levels. However, CII-BPI-2 did suppress induction of
IL-6; thus, the increase in IL-6 levels was not as high as in CII-2-
treated mice. This could also suggest that CII-BPI-2 and CII-2 have
entirely different mechanisms of action. These observations were
consistent with our findings with other BPI molecules. Even though
PLP-BPI was effective in suppressing EAE, its administration resulted
in an initial increase in IL-17 levels [26]. However, analysis of IL-6
levels in serum on day 44 showed that CII-BPI-2- and CII-2-treated
mice had significantly lower IL-6 levels compared to the control
group. All of these taken together indicate that CII-BPI-2 and CII-2
suppress disease by decreasing IL-6 response; this can, in turn,
suppress the downstream Th17 proliferation and perhaps enable a
shift in the balance toward T-regs proliferation. Also, decreasing the
serum levels of IL-6 inhibits osteoclastogenesis [11]. In arthritis,
osteoclasts are present in the inflamed synovium and contribute
greatly to the destruction of bone. Histopathology of the mice treated
with CII-BPI-2 confirmed the absence of osteoclasts.
In conclusion, CII-BPI-1 and CII-BPI-2 can suppress CIA more
effectively than their parent compounds. Tethering of the LABL
adhesion peptide to the CII peptide seems to better suppress CIA by
shifting the immune balance from a pro-inflammatory to a regulatory
response. Future studies will aim to better elucidate the mechanism of
the BPI peptide by studying other cytokine markers both in sera and in
splenocytes. Furthermore, optimization of the dose and dosing
schedule and utilization of a different route of delivery may lead to
better suppression of CIA.
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